{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:03Z","timestamp":1787026983280,"version":"build-2736575974"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitor (ICI)-associated aseptic meningitis is uncommon neurological immune-related adverse event that can cause substantial morbidity if appropriate immunosuppressive therapy is delayed while excluding infectious meningitis or leptomeningeal carcinomatosis is being evaluated. We report two lung adenocarcinoma cases illustrating an exclusion-based diagnostic process and stepwise immunosuppressive treatment of suspected ICI-associated aseptic meningitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case description<\/jats:title>\n                    <jats:p>Case 1: A 66-year-old woman experienced fever, neck stiffness, and altered mental status 13 days after initiating adjuvant atezolizumab. Cerebrospinal fluid (CSF) analysis showed pleocytosis and marked protein elevation, whereas neuroimaging remained unremarkable. After alternative diagnoses were excluded, high-dose intravenous methylprednisolone was administered, resulting in prompt improvement in consciousness and neurological symptoms, followed by oral corticosteroid tapering without recurrence. Case 2: A 75-year-old man receiving carboplatin\/nab-paclitaxel with durvalumab plus tremelimumab experienced ICI-associated colitis followed by Common Terminology Criteria for Adverse Events grade 3 meningitis with impaired consciousness. CSF multiplex polymerase chain reaction, cytological analysis, and further investigations supported early consideration that common infections and leptomeningeal carcinomatosis were unlikely, enabling timely immunosuppression for suspected ICI-associated aseptic meningitis. However, neurological deterioration continued despite high-dose corticosteroids and intravenous immunoglobulin. Consequently, tocilizumab was administered as rescue therapy, following which, both clinical outcomes and CSF parameters improved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These two cases illustrated a practical clinical approach to suspected ICI-associated aseptic meningitis based on rapid exclusion of alternative diagnoses and stepwise immunosuppressive treatment. High-dose corticosteroids remain the cornerstone of initial therapy, whereas additional immunomodulatory treatment might be considered in select refractory cases. CSF multiplex polymerase chain reaction might serve as an adjunctive tool in some patients by helping exclude common treatable infections during early diagnostic evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1877315","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:48:19Z","timestamp":1783403299000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: immune checkpoint inhibitor-associated aseptic meningitis in lung cancer: two cases illustrating an exclusion-based diagnosis approach and stepwise immunosuppressive treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Hiroshi","family":"Nakahama","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Hanada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital","place":["Tokyo, Japan"]},{"name":"Okinaka Memorial Institute for Medical Research","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Nei","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Mitsumura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyo","family":"Tamaoka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","article-title":"Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes","volume":"23","author":"Farina","year":"2024","journal-title":"Lancet Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2025-335998","article-title":"Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist","volume":"96","author":"Willis","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-022-03997-7","article-title":"Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review","volume":"157","author":"Nannini","year":"2022","journal-title":"J Neuro-Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/20420986211004745","article-title":"Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review","volume":"12","author":"Thouvenin","year":"2021","journal-title":"Ther Adv Drug Saf"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1654301","article-title":"Immune checkpoint inhibitor-associated aseptic meningitis: a pharmacovigilance study using the FDA adverse event reporting system (2011\u20132024)","volume":"16","author":"Guo","year":"2025","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101624","article-title":"Leptomeningeal metastasis from solid tumours: EANO\u2013ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"8","author":"Le Rhun","year":"2023","journal-title":"ESMO Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00730-16","article-title":"Multicenter evaluation of BioFire FilmArray Meningitis\/Encephalitis Panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens","volume":"54","author":"Leber","year":"2016","journal-title":"J Clin Microbiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2025.116823","article-title":"Clinical and cost implications of Biofire FilmArray\u00ae meningitis \/ encephalitis panel testing: a systematic review","volume":"112","author":"Rafiei","year":"2025","journal-title":"Diagn Microbiol Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007409","article-title":"Corticosteroid-resistant immune-related adverse events: a systematic review","volume":"12","author":"Daetwyler","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejim.2021.07.016","article-title":"Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series","volume":"93","author":"Campochiaro","year":"2021","journal-title":"Eur J Intern Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.2022.J071","article-title":"Cerebrospinal fluid interleukin-6 in immune checkpoint inhibitor-induced autoimmune meningoencephalitis","volume":"258","author":"Mizukami","year":"2022","journal-title":"Tohoku J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006814","article-title":"Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events","volume":"11","author":"Fa\u2019ak","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072399","article-title":"Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases","volume":"8","author":"Wullschleger","year":"2013","journal-title":"PloS One"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1877315\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:48:19Z","timestamp":1783403299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1877315\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":17,"alternative-id":["10.3389\/fonc.2026.1877315"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1877315","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1877315"}}